Antimalarial drug resistance markers in southeast Asia (2000–2025) - a systematic review protocol for surveillance and spatial mapping
DOI:
https://doi.org/10.15584/ejcem.2026.3.3Keywords:
drug-resistant malaria, Greater Mekong sub-region, Plasmodium falciparum, southeast Asia, systematic review protocolAbstract
Introduction and aim. Southeast Asia has historically been the epicenter of drug resistance against Plasmodium falciparum. The resistance has markedly reduced the effectiveness of key antimalarial drugs, such as chloroquine, sulfadoxine-pyrimethamine, and artemisinin-based combination therapy (ACTs). This systematic review protocol aims to characterize the spatio-temporal distribution and trends of drug resistance markers, both molecular and phenotypic, in P. falciparum malaria across Southeast Asian countries from 2000 to 2025 and to identify regional research and surveillance gaps.
Material and methods. This study will follow a systematic search of literature published in English with full text from January 2000 to December 2025, including grey literature from five electronic databases. Data extraction and analysis will strictly adhere to the PRISMA-P guidelines and PECO/PICO framework. Risk of bias will be assessed independently by two reviewers using the Joanna Briggs Institute (JBI) critical appraisal tools matched to study design, including the JBI Analytical Cross-Sectional Checklist for molecular surveillance studies and the JBI Prevalence Checklist for epidemiological surveys.
Expected outcomes. This systematic protocol is expected to synthesize evidence on the prevalence, geographical distribution, and temporal trends of resistance markers and treatment failure associated with drug-resistant P. falciparum in Southeast Asia.
Downloads
References
Hyde JE. Drug-resistant malaria - an insight. FEBS J. 2007;274(18):4688-4698. doi:10.1111/j.1742-4658.2007.05999.x
Amato R, Pearson RD, Almagro-Garcia J, et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis. 2018;18(3):337-345. doi:10.1016/S1473-3099(18)30068-9
Li Q, Liu T, Lv K, et al. Malaria: past, present, and future. Signal Transduct Target Ther. 2025;10:188. doi:10.1038/s41392-025-02246-3
World Health Organization. Status Report on Artemisinin Resistance and ACT Efficacy. World Health Organization; 2018.
MalariaGEN Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin-resistant malaria. eLife. 2016;5:e08714. doi:10.7554/eLife.08714
Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359(24):2619-2620. doi:10.1056/NEJMc0805011
Hassett MR, Roepe PD. Origin and spread of evolving artemisinin-resistant Plasmodium falciparum malarial parasites in Southeast Asia. Am J Trop Med Hyg. 2019;101(6):1204-1211. doi:10.4269/ajtmh.19-0379
Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455-467. doi:10.1056/NEJMoa0808859
Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50-55. doi:10.1038/nature12876
Wang Z, Shrestha S, Li X, et al. Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007-2012. Malar J. 2015;14:168. doi:10.1186/s12936-015-0672-9
Xie SC, Ralph SA, Tilley L. K13, the cytostome, and artemisinin resistance. Trends Parasitol. 2020;36(6):533-544. doi:10.1016/j.pt.2020.03.006
Imwong M, Dhorda M, Tun KM, et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong Subregion: an observational study. Lancet Infect Dis. 2020;20(12):1470-1480. doi:10.1016/S1473-3099(20)30228-0
White NJ, Chotivanich K. Artemisinin-resistant malaria. Clin Microbiol Rev. 2024; 37(4):e0010924. doi:10.1128/cmr.00109-24
Landier J, Parker DM, Thu AM, et al. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet. 2018;391(10133):1916-1926. doi:10.1016/S0140-6736(18)30491-4
World Health Organization. Mekong Malaria Elimination Programme Epidemiology Summary. Vol 29. World Health Organization; 2025.
Pley C, Gibbs H, Sudathip P, et al. Impact of the Global Fund Regional Artemisinin-resistance Initiative on malaria control and elimination in the Greater Mekong Subregion of Southeast Asia. Lancet Infect Dis. 2025;25(6):e353-e359. doi:10.1016/S1473-3099(25)00013-1
Edwards H, Canavati SE, Rang C, et al. Novel cross-border approaches to optimise identification of asymptomatic and artemisinin-resistant Plasmodium infection in mobile populations crossing Cambodian borders. PLoS One. 2015;10(9):e0124300. doi:10.1371/journal.pone.0124300
Chigozie VU, Aniokete CU, Ogbonna PI, et al. Transforming antimicrobial resistance mitigation: the genomic revolution in one health and public health. Discov Appl Sci. 2025;7(10):1187. doi:10.1007/s42452-025-07053-7
Hamilton WL, Amato R, van der Pluijm RW, et al. Evolution and expansion of multidrug-resistant malaria in Southeast Asia: a genomic epidemiology study. Lancet Infect Dis. 2019;19(9):943-951. doi:10.1016/S1473-3099(19)30392-5
Balmer AJ, White NFD, Ünlü ES, et al. Understanding the global rise of artemisinin resistance: insights from over 100,000 Plasmodium falciparum samples. eLife. 2025;14:e105544. doi:10.7554/eLife.105544
Weiss DJ, Dzianach PA, Saddler A, et al. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000-2022: a spatial and temporal modelling study. Lancet. 2025;405:979-990. doi:10.1016/S0140-6736(25)00038-8
Joanna Briggs Institute. Critical Appraisal Checklist for Systematic Reviews and Research Syntheses. Joanna Briggs Institute; 2017.
Mayxay M, Barends M, Brockman A, et al. In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos). Am J Trop Med Hyg. 2007;76:245-250.
Habarugira F, Batamuriza J, Ndahimana R, et al. The global landscape of Plasmodium falciparum drug resistance markers, 2005-2025: a systematic review and meta-analysis. Pathogens. 2026;15(2):179. doi:10.3390/pathogens15020179
Miller MA, Astuti R, Hirsch P, et al. Selective border permeability: governing complex environmental issues through and beyond COVID-19. Polit Geogr. 2022;97:102646. doi:10.1016/j.polgeo.2022.102646
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
